Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

BACKGROUND: Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access by offering patients a more affordable option, lead to improved patient outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Katchamart, Wanruchada, Ngamjanyaporn, Pintip, Orawongpaisarn, Annop, Phubangkertphon, Thossapoom, Borrirukwisitsak, Sasimon, Dechapaphapitak, Nichapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710159/
https://www.ncbi.nlm.nih.gov/pubmed/36447248
http://dx.doi.org/10.1186/s41927-022-00306-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710159/
https://www.ncbi.nlm.nih.gov/pubmed/36447248
http://dx.doi.org/10.1186/s41927-022-00306-7

Ejemplares similares